Table 2.
Folate & CRC/A recurrence.
| Study | Sample size (N) | Dose (MG/DAY) | Duration | Effect on CRA recurrence |
|---|---|---|---|---|
| Greece (1994) (26) | 60 | 1 | 2 years (YR) | No effect |
| AFPPS (2007) (12) | 1021 | 1 | 6 YR | 67% increased risk |
| Detroit VA (2008) (28) | 94 | 5 | 3 YR | 46% decreased risk |
| (UKCAP) (2008) (27) | 853 | 0.5 | 3 YR | No effect |
| (NHS-HPFS) (2009) (22) | 672 | 1 | 3 YR | No effect |
| Ibrahim, Ezzeldin M, and Jamal M Zekri Meta-analysis (2010) (25) | 1580 | 1 | 1-3 YR | No effect |
| Combined Analysis of AFPPS, NHS-HPFS, & UKCAP (2011) (30) | 2632 | 0.5–1 | 6–42 months | No effect |
| Meta-Analysis of AFPPS, NHS-HPFS, & UKCAP (2013) (31) | 2632 | 0.5–1 | 3-6 YR | Increased risk |
| Focus CONSORTIUM (2020) (19) | 2024 | – | a | No effect |
a
The FOCUS consortium includes 6 cohorts.
-
-The COLON [34](n = 1094) and EnCoRe [35](n = 297) studies are ongoing prospective cohort studies that recruit newly diagnosed colorectal cancer patients since 2010 and 2012, respectively. (from eleven hospitals in the Netherlands for the COLON study and from three hospitals in the Netherlands for the EnCoRe study).
-
-CORSA [36](n = 209) is an ongoing study since 2003, recruiting colorectal cancer patients in cooperation with the province-wide screening project “Burgenland Prevention Trial of Colorectal Disease with Immunological Testing” (B-PREDICT) using fecal occult blood testing (FOBT).
-
-ColoCare [36] is an ongoing, international, prospective cohort study. Patients were recruited since 2010 at the University Hospital of Heidelberg and the National Center for Tumor Diseases in Heidelberg, Germany(n = 260) (ColoCare HD). ColoCare patients were also recruited since 2015 at Huntsman Cancer Institute(n = 46) (Salt Lake City, U.S.) (ColoCare HCI) and since 2007 at Fred Hutchinson Cancer Research Center(n = 118) (Seattle, U.S.) (ColoCare FHCRC).